Multiple myeloma is an incurable, disseminated malignancy of terminally differentiated plasma cells that will be responsible for the deaths of more than 11,000 Americans in 2006. Attenuated measles viruses are selectively destructive to human myeloma plasma cells which express abundant CD46 (the viral receptor) and are therapeutically potent in murine myeloma xenograft models. We are therefore testing a recombinant measles virus by intravenous administration in patients with advanced, treatment-refractory multiple myeloma. Neutralizing antimeasles antibodies are expected to limit the therapeutic efficacy of the systemically administered measles viruses, particularly in those 70% of myeloma patients with higher antibody titers. The goal of this proposal is to develop optimal strategies to combat measles virus neutralization in the bloodstream by suppressing the production of antimeasles antibodies, or by delivering the virus inside autologous monocytes or dendritic cells, infected outside the body. The findings of these studies will be used to guide the design of future clinical trials of measles virotherapy in myeloma patients.
Specific aims are as follows:
Aim 1. Develop a clinically viable strategy using cyclophosphamide in combination with measles booster vaccination to reduce the plasma concentration of neutralizing anti-measles antibodies.
Aim 2. Evaluate the performance of measles-infected monocytes, or monocyte-derived dendritic cells (immature or mature) as antibody-resistant virus delivery vehicles.
Aim 3. Determine whether suppression of CCR7 chemokine receptor expression can favorably impact the biodistribution of measles-infected dendritic cells in CD46 transgenic SCID mice. Antibodies are the most important barrier to the successful deployment of viruses as anticancer agents. This grant seeks to develop clinical viable solutions to this problem.
|Suksanpaisan, L; Russell, S J; Peng, K-W (2014) High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus. Cancer Gene Ther 21:256-60|
|Lech, Patrycja J; Pappoe, Roland; Nakamura, Takafumi et al. (2014) Antibody neutralization of retargeted measles viruses. Virology 454-455:237-46|
|Ayala-Breton, Camilo; Russell, Luke O J; Russell, Stephen J et al. (2014) Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus. J Virol 88:8332-9|
|Miller, Amber; Suksanpaisan, Lukkana; Naik, Shruthi et al. (2014) Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy. Mol Ther Oncolytics 1:14005|
|Suksanpaisan, L; Pham, L; McIvor, S et al. (2013) Oral contrast enhances the resolution of in-life NIS reporter gene imaging. Cancer Gene Ther 20:638-41|
|Lech, Patrycja J; Tobin, Gregory J; Bushnell, Ruth et al. (2013) Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies. PLoS One 8:e52306|
|Peng, K-W; Myers, R; Greenslade, A et al. (2013) Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther 20:255-61|
|Yarde, D N; Naik, S; Nace, R A et al. (2013) Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV. Cancer Gene Ther 20:616-21|
|Ayala-Breton, Camilo; Suksanpaisan, Lukkana; Mader, Emily K et al. (2013) Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread. Mol Ther 21:1930-7|
|Liu, Chunsheng; Suksanpaisan, Lukkana; Chen, Yun-Wen et al. (2013) Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp Hematol 41:508-17|
Showing the most recent 10 out of 27 publications